Manmeet Singh Soni - 29 Apr 2025 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Reporting relationship: COO and CFO, Director
Issuer ticker: SMMT
Reported as of: 29 Apr 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 May 2025, 18:13:55 UTC
Prior SEC filing: 13 Sep 2024
Next SEC filing: 19 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Manmeet Soni

Key filing fact

Manmeet Singh Soni filed Form 4 for Summit Therapeutics Inc. (SMMT) on 01 May 2025.

Key facts

This page summarizes Manmeet Singh Soni's Form 4 filing for Summit Therapeutics Inc. (SMMT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 May 2025, 18:13.

Change

Previous filing in this sequence was filed on 13 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SMMT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +11,200,000
Change %
Price
Shares after: 11,200,000
Date: 29 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,200,000
Exercise price: $1.68
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest as follows: (i) 50% of such shares vested as of April 29, 2025, and (ii) the remaining 50% of such shares vest in three equal annual installments, with the first such installment occurring on October 13, 2025.

Footnote F2

Not applicable.